Drug Origin Transparency Act of 2026
In committee: it can still change before the session ends.
- Stage
- In committee
- Started in
- House
- Sponsors
- 4
- Latest action
- Apr 16, 2026
What it does
The Drug Origin Transparency Act of 2026 would amend the Federal Food, Drug, and Cosmetic Act to require more detailed and frequent reporting of drug manufacturing data, including the identity and quantities of active pharmaceutical ingredients and intermediates supplied by each vendor in the supply chain, with reports due up to four times per year. It would also mandate that drug labels include the name, place of business, and unique facility identifier of the original manufacturer of the drug and each active pharmaceutical ingredient, as well as any subsequent manufacturers, packers, or distributors, with flexibility for the Secretary of Health and Human Services to allow reasonable…
No official summary is available here. This one was written by AI from the bill’s text.
Where it stands
Introduced (Done)
Committee (Current step)
Floor (Not started)
Law (Not started)
What moved
Who is involved
Sponsors
The lawmakers who put their names on it, lead sponsors first.
Where it goes next
While a bill can still move, the questions are about people and money.